• Benign Prostatic Hyperplasia
  • Hormone Therapy
  • Genomic Testing
  • Next-Generation Imaging
  • UTUC
  • OAB and Incontinence
  • Genitourinary Cancers
  • Kidney Cancer
  • Men's Health
  • Pediatrics
  • Female Urology
  • Sexual Dysfunction
  • Kidney Stones
  • Urologic Surgery
  • Bladder Cancer
  • Benign Conditions
  • Prostate Cancer

Drug therapy reduces risk of rejection in kidney transplant patients

Article

Treatment with anti-thymocyte globulin (rabbit [Thymoglobulin]) results in a significantly reduced risk of acute rejection and acute rejection requiring antibody therapy and a similar risk of delayed graft function, graft loss, and death in kidney transplant patients compared with patients receiving induction therapy with basiliximab (Simulect), according to a study published this month in the New England Journal of Medicine (2006; 355:1967-77).

Treatment with anti-thymocyte globulin (rabbit [Thymoglobulin]) results in a significantly reduced risk of acute rejection and acute rejection requiring antibody therapy and a similar risk of delayed graft function, graft loss, and death in kidney transplant patients compared with patients receiving induction therapy with basiliximab (Simulect), according to a study published this month in the New England Journal of Medicine (2006; 355:1967-77).

The study involved 278 patients at high risk for acute rejection or delayed graft function following a kidney transplant from a deceased donor. At 12 months, the incidence of a composite endpoint (first occurrence of acute rejection, delayed graft function, graft loss, and death) was similar in the two groups (50.4% for the anti-thymocyte globulin group vs. 56.2% for the basiliximab group, p=.34).

The anti-thymocyte globulin group had a 38.8% lower incidence of acute rejection compared with the basiliximab group (15.6% vs. 25.5%, p=.02) and an 82.5% lower incidence of severe acute rejection requiring treatment with antibody (1.4% vs. 8%, p=.005).

“Our study showed the risk of acute rejection was about 1.5 times higher among patients treated with basiliximab, and the need for antibody treatment related to acute rejection was six times higher among the basiliximab group,” said first author Daniel C. Brennan, MD, of Washington University School of Medicine, St. Louis. “These results are an important contribution to our understanding of these treatment approaches, and we look forward to examining the longer-term outcomes of these patients.”

The study was supported by SangStat Medical Corp. and Genzyme.

Related Videos
Gary D. Steinberg, MD, an expert on bladder cancer
Akhil Das, MD, FACS, answers a question during a video interview
Edward M. Schaeffer, MD, PhD, answers a question during a Zoom video interview
Woman talking with doctor | Image Credit: © rocketclips - stock.adobe.com
Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
Gamal M. Ghoniem, MD, FACS, ABU/FPMRS, gives an answer during a video interview
Related Content
© 2024 MJH Life Sciences

All rights reserved.